bluebird bio Completes NIH RAC Review of HGB-208 Pediatric Study Protocol
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St kicks off September under pressure as higher yields, oil prices weigh
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
BMO Capital Sees 'Deminimus Impact' on bluebird bio (BLUE) Valuation Even If Launch Delayed
June 10, 2015 8:06 AM EDTBMO Capital analyst Jim Birchenough reiterated an Outperform rating and $200 price target on bluebird bio (NASDAQ: BLUE) after the company announced late yesterday that the NIH's Recombinant DNA Advisory Committee (RAC) has recommended delaying initiation of the HGB-208 pediatric study protocol by 1-2... More
RCA HGB-208 Pushback Seen as 'Modest Stumble', Roth Capital Says
June 10, 2015 7:03 AM EDTRoth Capital analyst Debjit Chattopadhyay maintained a Buy rating and $192 price target on bluebird bio (NASDAQ: BLUE) following news after the close the RAC recommendation on the HGB-208 study (pediatrics,... More
bluebird bio (BLUE) Say NIH's RAC Recommends Delay of HGB-208 Pediatric Study for 1-2 Years
June 9, 2015 6:43 PM EDTbluebird bio, Inc. (Nasdaq: BLUE) announced today the completion of the National Institutes of Health (NIH) Recombinant DNA Advisory Committees (RAC) public review of the HGB-208 pediatric study protocol for bluebird bios LentiGlobin BB305 product candidate in beta-thalassemia major. The RAC recommendation was to delay initiation of the study in the United States for one to two years. This recommendation has no effect on the HGB-207 protocol plan.
We appreciate the recommendations from the RAC members regarding the HGB-208 pediatric study protocol, said David Davidson, M.D., chief medical officer. We... More
